Executive Board Changes at Merck
The Personnel Committee of E. Merck KG has decided on changes in the responsibilities of the Executive Board of Merck KGaA, Darmstadt, effective September 1, 2017.
Walter Galinat (61) will hand over responsibility for the Performance Materials business of Merck to his Executive Board colleague Kai Beckmann (51). In return, Galinat will take on Executive Board responsibility for the Darmstadt site, Procurement as well as Environmental Protection, Quality and Safety.
“With these changes to the Executive Board, we are underscoring personnel continuity within the Board while setting the course for the future of Performance Materials,” said Johannes Baillou, Chairman of the Board of Partners of E. Merck KG and its Personnel Committee. In addition, in his new role Galinat will further advance both the construction and organizational preparations for the 350th anniversary celebration of Merck in 2018.
“Over the past decade, Walter Galinat has led Performance Materials from one success to the next. We are very grateful to him for this. At the same time, we are pleased to continue building on his vast wealth of experience,” said Baillou. “As an experienced member of Merck’s Executive Board, Kai Beckmann has extensive business, technological and international expertise, among other things from the very important Asian market. For him and for Merck, the aim now is to build on the long and successful development of Performance Materials, leading it into the future in times of increasingly dynamic developments in the liquid crystals market.”
Belén Garijo (57), CEO Healthcare, will additionally take over Executive Board responsibility for Group Human Resources from Kai Beckmann. Udit Batra (46), CEO Life Science, will be responsible for Business Technology, in other words the IT landscape of the Merck Group. In addition to his role as Chief Financial Officer, Marcus Kuhnert (48) will be responsible for Merck Business Services, a newly formed unit.
Most read news
Other news from the department people

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents
Norwood_(charity)

Schizophrenia manifests itself in the brain structure - The symptoms of schizophrenia vary greatly from person to person

ImageBiopsy Lab - Wien, Austria
Eppendorf grows faster than the market
La Jolla Institute finds previous seasonal flu infections may provide some level of H1N1 immunity

Sequential antibiotic therapy in the laboratory and in patients - Rapid switching between different antibiotics could prevent the evolution of resistance and lead to successful treatment of patients

dimes AUTOMATION GmbH - Bonn, Germany
Q Chip appoints Tim Sparey as Chief Executive Officer - Completes £2.0 Million Funding Round

Suffocating cancer cells - Self-assembling molecules could help in cancer therapy

HM-Software - Adelheidsdorf, Germany

Lumiphore, Inc. - Richmond, USA
